 Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA |
| The invention is directed to a new method of inducing viral mutagenesis which is useful in cell ... |
|
| 2'-Fluoronucleosides |
| OF THE INVENTION The invention as disclosed herein is a compound, method and composition for the ... |
|
| Nucleoside compounds |
| Where the following terms are used in this specification, they are used as defined below. The ... |
|
| Method for the treatment of Flaviviridea viral infection using nucleoside analogues |
| OF THE INVENTION In one embodiment, the viral infection is chosen from Flaviviridea viral ... |
|
| Monocyclic L-nucleosides, analogs and uses thereof |
| Where the following terms are used in this specification, they are used as defined below. The term ... |
|
| Storage medium storing catalog information and corresponding audio data |
| It is an object of the present invention to provide a storage medium for storing catalog ... |
|
| Nucleoside compounds and uses thereof |
| The present invention is directed to nucleoside analogs and related compounds, including their ... |
|
| Composition and method for inhibiting platelet aggregation |
| OF THE INVENTION This invention is provides a method of preventing or treating diseases or ... |
|
| Non-infectious HIV particles and uses therefor |
| The present invention relates to HIV mutant constructs comprising a mutant HIV genome which has an ... |
|
|
Saponin adjuvant compositions
| Details |
Inventors: Kensil, Charlotte A.;
Assignee: Aquila Biopharmaceuticals, Inc. (Framingham, MA)
Primary Examiner: Saunders; David
Assistant Examiner:
Attorney, Agent or Firm: Hale and Dorr LLP
The present invention is in the field of medicinal chemistry. In particular, the invention is related to vaccines comprising novel combinations of saponin adjuvants, to pharmaceutical compositions and vaccines comprising these novel combinations, to methods of using these novel combinations to enhance the immune response of an individual to an antigen, and to the use of the novel combinations to increase the immunogenicity of vaccines. |
|
DETAILED DESCRIPTION What is claimed is: 1.
A Quillaja saponaria saponin composition for eliciting an immune response in an organism, comprising a combination of a substantially pure QS-7 saponin and a substantially pure saponin selected from the group consisting of: (a) QS-17, (b) QS-18, (c) QS-21, (d) QS-21-V1, and (e) QS-21-V2, wherein the substantially purified saponins of the combination are present in suboptimal dosages for the organism, and wherein in the presence of an antigen, the combination has a synergistic adjuvant effect in eliciting the immune response.
2.
The saponin composition of claim 1, wherein the substantially pure saponins comprise QS7 and QS-21.
3.
The saponin composition of claim 1, wherein the substantially pure saponins comprise QS-7 and QS-21 V1.
4.
The saponin composition of claim 1, wherein the substantially pure saponins comprise QS-7 and QS-21 V2.
5.
The saponin composition of claim 1, wherein the substantially pure saponins comprise QS-7 and QS-17.
6.
The saponin composition of claim 1, wherein the substantially pure saponins comprise QS-7 and QS-18.
7.
A Quillaja saponaria saponin composition for eliciting an immune response in an organism, comprising a combination of a substantially pure QS-21-V1 saponin and a substantially pure saponin selected from the group consisting of: (a) QS-17, and (b) QS-18, wherein the substantially purified saponins of the combination are present in suboptimal dosages for the organism, and wherein in the presence of an antigen, the combination has a synergistic adjuvant effect in eliciting the immune response.
8.
The saponin composition of claim 7, wherein the saponin composition comprises a substantially pure QS-21-V1 saponin and a substantially pure QS-17 saponin.
9.
The saponin composition of claim 7, wherein the saponin composition comprises a substantially pure QS-21-V1 saponin and a substantially pure QS-18 saponin.
10.
A Quillaja saponaria saponin composition for eliciting an immune response in an organism, comprising a combination of a substantially pure QS-21-V2 saponin and a substantially pure saponin selected from the group consisting of: (a) QS-17, and (b) QS-18, wherein the substantially purified saponins of the combination are present in suboptimal dosages for the organism, and wherein in the presence of an antigen, the combination has a synergistic adjuvant effect in eliciting the immune response
|
| Related patents |
|
|
Quercetin derivatives and their medical usages
The invention claimed is: 1. A purified compound of formula I ##STR00002## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4 are all or partly hydrogen atoms, or alkyl ...
|
|
|
Islet cells from human embryonic stem cells
This invention solves the problem of generating large populations of human islet cells by showing how to efficiently differentiate them from pluripotent stem cells. It ...
|
|
|
Neural thread protein gene expression and detection of alzheimer's disease
A need exists for a definitive diagnostic test which can be performed on individuals suspected of having, or being at risk for AD. The present invention satisfies such ...
|
|
|
Method of detecting neurological disease or dysfunction
What is claimed is: 1. A method for detecting the presence of nPTP in a human subject, said method comprising: (a) contacting cerebrospinal fluid or brain tissue removed ...
|
|
|
Metabolic pathway assay
This invention relates to an in vitro screening assay which identifies enzyme inhibitors. This invention allows for the simultaneous assay of many enzymes. The goal is ...
|
|
|
MurC
What is claimed is: 1. An isolated polynucleotide segment comprising a first polynucleotide sequence or the full complement of the entire length of the first ...
|
|
|
Murf gene and enzyme of Pseudomonas aeruginosa
Polynucleotides and polypeptides of Pseudomonas aeruginosa MurF, an enzyme involved in bacterial cell wall biosynthesis are provided. The recombinant MurF enzyme is ...
|
|
|
Isoform specific inhibition for treatment of pain and reduction of anesthetic threshold
It is an object of the invention to provide a method of affecting nociception. It is an object of the invention to provide a catheter for treating pain. It is an object ...
|
|
|
Liposomal transfection method
The object of the present invention is thus a method for transfecting a cell with a nucleic acid which comprises contacting the cell with a liposomal transfection ...
|
|
|
Antihelminthic anthraquinones and method of use thereof
OF THE INVENTION All patents, patent applications, government publications, government regulations, and literature references cited in this specification are hereby ...
|
|
|
Gene Therapy 
